Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush October 16, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6 billion by 2033, with institutional investors pouring capital into companies developing breakthrough treatments that target aging at the cellular level[1]. FDA accelerated approval pathways for revolutionary CAR-T therapies and stem cell treatments have created a regulatory tailwind that's transforming scientific breakthroughs into commercial realities, while the convergence of artificial intelligence with biotech research has compressed development timelines from decades to years[2]. This perfect storm of demographic urgency, technological advancement, and regulatory momentum has positioned select biotechnology companies at the forefront of what analysts call medicine's next trillion-dollar frontier: Avant Technologies, Inc. (OTCQB: AVAI), Xencor, Inc. (NASDAQ: XNCR), Editas Medicine, Inc. (NASDAQ: EDIT), Autolus Therapeutics plc (NASDAQ: AUTL), and Denali Therapeutics Inc. (NASDAQ: DNLI). HTF Market Intelligence forecasts the longevity biotech market will expand at 16.5% CAGR through 2033, with venture capital firms that previously retreated now racing to deploy billions into cell therapy developers showing promise in clinical trials, while major pharmaceutical companies hunt for acquisition targets to fill pipelines facing a $300 billion patent cliff[3]. The acceleration of FDA approvals for gene therapies treating previously incurable conditions has shifted institutional sentiment from skepticism to urgency, creating a narrow window for investors to position themselves before these transformative treatments reach mainstream adoption and valuations reflect their revolutionary potential to extend human healthspan by decades. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic transformation of its business model, pivoting toward a partnership-driven approach focused on innovative cell-based therapies targeting chronic and age-related conditions. The company has also applied for a corporate name change to better reflect this refined mission, positioning Avant at the forefront of collaborative biotech innovation through joint ventures and licensing agreements that identify promising cell lines globally and forge alliances with leading biotech companies, scientists, and clinicians. This new model enables Avant and its partners to leverage complementary expertise and resources while mitigating traditional development costs and risks. Key therapeutic areas include diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, kidney disease, and longevity promotion. Central to Avant's approach are partnerships with biotech companies specializing in genetically modified cell lines designed to perform essential bodily functions that may be deficient in patients, combined with collaboration with a leading global cell-encapsulation technology firm to safeguard these cells during therapeutic applications, ensuring their efficacy and safety in development programs. "Our transition to a partnership-driven model represents a transformative step for Avant, enabling us to harness global innovations in cell therapy while mitigating traditional development challenges," said Chris Winter, CEO of Avant. "By combining forces with top-tier experts, we're not just identifying diseases - we're actively developing solutions that could change lives." Avant's first joint venture with Ainnova Tech, Inc. integrates an advanced Vision AI platform to detect a spectrum of diseases, including diabetes-related complications, through non-invasive diagnostics. Building on this foundation, the company's latest joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.) established Klothonova, Inc. as a 50/50 partnership focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. This unique ecosystem of joint ventures empowers Avant to bridge the gap between disease detection and targeted treatment, fostering rapid advancements in personalized medicine. The Klothonova venture leverages Austrianova's proprietary Cell-in-a-Box® technology with 30+ years of development, backed by over 50 peer-reviewed publications and established partnerships with global pharmaceutical companies. The scientific foundation appears compelling: studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels. Critically, natural Klotho levels drop by 50% after age 40, creating substantial therapeutic intervention opportunities for this crucial "longevity protein" that modulates aging processes while affecting brain, heart, kidneys, and immune function simultaneously. The market opportunity spans multiple therapeutic areas. The global Alzheimer's disease market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. This strategic transformation positions Avant within the rapidly expanding longevity biotechnology sector, with multiple joint ventures creating complementary pathways for value creation as cell-based treatments advance toward clinical validation and commercialization across global markets. CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ Denali Therapeutics Inc. (NASDAQ: DNLI) announced the FDA has extended its review timeline for tividenofusp alfa, a potential breakthrough therapy for Hunter syndrome that crosses the blood-brain barrier to address both neurological and physical symptoms. The PDUFA target date has been extended from January 5, 2026, to April 5, 2026, following Denali's submission of updated clinical pharmacology information unrelated to efficacy or safety concerns. "We appreciate the FDA's continued collaboration throughout the review process," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We continue to prepare for the potential approval and commercial launch of tividenofusp alfa. We feel the urgency to deliver for the MPS community, and we are committed to working together with regulators, physicians, and advocates to bring this important therapy to individuals and families living with Hunter syndrome." The Phase 2/3 COMPASS study continues enrolling participants across North America, South America, and Europe to support global approval. With Fast Track and Breakthrough Therapy designations from the FDA and Priority Medicines designation from the European Medicines Agency, tividenofusp alfa represents a significant advancement in addressing the unmet need for therapies targeting central nervous system manifestations of Hunter syndrome. Autolus Therapeutics plc (NASDAQ: AUTL) will present updated clinical data from its CARLYSLE study of obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-cell therapy with a fast off-rate binding domain, in patients with severe refractory systemic lupus erythematosus at the American College of Rheumatology Convergence 2025. Initial findings demonstrated a manageable safety profile with no dose limiting toxicities, immune effector cell-associated neurotoxicity syndrome, or Grade ≥2 cytokine release syndrome, along with SLEDAI-2K score reductions and clinical benefit observed in all patients, including three who achieved complete renal response. The presentation on October 28, 2025, will feature updated follow-up data from this ongoing Phase I study, marking an important milestone in Autolus's expansion beyond oncology into autoimmune diseases with its proprietary CAR T platform that has already delivered AUCATZYL® as its first marketed therapy. Editas Medicine, Inc. (NASDAQ: EDIT) reported in vivo proof-of-concept data for EDIT-401, achieving ≥90% mean LDL-cholesterol reduction within 48 hours in non-human primates and similar results in mouse models with high baseline LDL-C. The experimental one-time therapy uses CRISPR/Cas9 nuclease with dual gRNAs delivered via LNP to disrupt negative regulatory elements, resulting in a ≥6-fold mean increase in LDLR protein in the liver. "The in vivo proof-of-concept data presented today reinforce the potential impact of our differentiated upregulation strategy," said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer of Editas Medicine. "In preclinical non-human primate studies, EDIT-401 achieved robust efficacy data with a ≥90% mean LDL-C reduction. These data strengthen our conviction that EDIT-401 represents a novel therapeutic approach with the potential to significantly improve outcomes for people living with high LDL cholesterol." The durable effects were maintained in mouse models throughout a three-month study period, supporting Editas's approach of functionally upregulating LDLR rather than traditional knockdown strategies. As the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines, Editas continues advancing its pipeline of precision in vivo gene editing medicines. Xencor, Inc. (NASDAQ: XNCR) recently announced the upcoming presentation of initial Phase 1 results for XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with clear cell renal cell carcinoma at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. The tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody targets ENPP3, an antigen highly expressed on kidney cancers with minimal expression on normal tissues, leveraging Xencor's proprietary platform that enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density. The presentation will include detailed safety analysis and efficacy results from the target dose range of the ongoing dose-escalation study (NCT05433142), with management hosting a webcast to discuss findings from this novel therapeutic approach that activates T cells for highly potent and targeted lysis of tumor cells while potentially sparing normal cells. Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES CITED 1. https://www.openpr.com/news/4225415/longevity-and-wellness-biotech-market-hits-new-high-major 2. https://www.pharmiweb.com/press-release/2025-10-14/cell-therapy-market-2035-driving-breakthroughs-in-oncology-and-regenerative-medicine 3. https://www.openpr.com/news/4225415/longevity-and-wellness-biotech-market-hits-new-high-major
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush October 16, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6 billion by 2033, with institutional investors pouring capital into companies developing breakthrough treatments that target aging at the cellular level[1]. FDA accelerated approval pathways for revolutionary CAR-T therapies and stem cell treatments have created a regulatory tailwind that's transforming scientific breakthroughs into commercial realities, while the convergence of artificial intelligence with biotech research has compressed development timelines from decades to years[2]. This perfect storm of demographic urgency, technological advancement, and regulatory momentum has positioned select biotechnology companies at the forefront of what analysts call medicine's next trillion-dollar frontier: Avant Technologies, Inc. (OTCQB: AVAI), Xencor, Inc. (NASDAQ: XNCR), Editas Medicine, Inc. (NASDAQ: EDIT), Autolus Therapeutics plc (NASDAQ: AUTL), and Denali Therapeutics Inc. (NASDAQ: DNLI). HTF Market Intelligence forecasts the longevity biotech market will expand at 16.5% CAGR through 2033, with venture capital firms that previously retreated now racing to deploy billions into cell therapy developers showing promise in clinical trials, while major pharmaceutical companies hunt for acquisition targets to fill pipelines facing a $300 billion patent cliff[3]. The acceleration of FDA approvals for gene therapies treating previously incurable conditions has shifted institutional sentiment from skepticism to urgency, creating a narrow window for investors to position themselves before these transformative treatments reach mainstream adoption and valuations reflect their revolutionary potential to extend human healthspan by decades. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic transformation of its business model, pivoting toward a partnership-driven approach focused on innovative cell-based therapies targeting chronic and age-related conditions. The company has also applied for a corporate name change to better reflect this refined mission, positioning Avant at the forefront of collaborative biotech innovation through joint ventures and licensing agreements that identify promising cell lines globally and forge alliances with leading biotech companies, scientists, and clinicians. This new model enables Avant and its partners to leverage complementary expertise and resources while mitigating traditional development costs and risks. Key therapeutic areas include diabetes, anti-aging, Alzheimer's disease, heart disease, cancer, kidney disease, and longevity promotion. Central to Avant's approach are partnerships with biotech companies specializing in genetically modified cell lines designed to perform essential bodily functions that may be deficient in patients, combined with collaboration with a leading global cell-encapsulation technology firm to safeguard these cells during therapeutic applications, ensuring their efficacy and safety in development programs. "Our transition to a partnership-driven model represents a transformative step for Avant, enabling us to harness global innovations in cell therapy while mitigating traditional development challenges," said Chris Winter, CEO of Avant. "By combining forces with top-tier experts, we're not just identifying diseases - we're actively developing solutions that could change lives." Avant's first joint venture with Ainnova Tech, Inc. integrates an advanced Vision AI platform to detect a spectrum of diseases, including diabetes-related complications, through non-invasive diagnostics. Building on this foundation, the company's latest joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.) established Klothonova, Inc. as a 50/50 partnership focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. This unique ecosystem of joint ventures empowers Avant to bridge the gap between disease detection and targeted treatment, fostering rapid advancements in personalized medicine. The Klothonova venture leverages Austrianova's proprietary Cell-in-a-Box® technology with 30+ years of development, backed by over 50 peer-reviewed publications and established partnerships with global pharmaceutical companies. The scientific foundation appears compelling: studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels. Critically, natural Klotho levels drop by 50% after age 40, creating substantial therapeutic intervention opportunities for this crucial "longevity protein" that modulates aging processes while affecting brain, heart, kidneys, and immune function simultaneously. The market opportunity spans multiple therapeutic areas. The global Alzheimer's disease market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. This strategic transformation positions Avant within the rapidly expanding longevity biotechnology sector, with multiple joint ventures creating complementary pathways for value creation as cell-based treatments advance toward clinical validation and commercialization across global markets. CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ Denali Therapeutics Inc. (NASDAQ: DNLI) announced the FDA has extended its review timeline for tividenofusp alfa, a potential breakthrough therapy for Hunter syndrome that crosses the blood-brain barrier to address both neurological and physical symptoms. The PDUFA target date has been extended from January 5, 2026, to April 5, 2026, following Denali's submission of updated clinical pharmacology information unrelated to efficacy or safety concerns. "We appreciate the FDA's continued collaboration throughout the review process," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We continue to prepare for the potential approval and commercial launch of tividenofusp alfa. We feel the urgency to deliver for the MPS community, and we are committed to working together with regulators, physicians, and advocates to bring this important therapy to individuals and families living with Hunter syndrome." The Phase 2/3 COMPASS study continues enrolling participants across North America, South America, and Europe to support global approval. With Fast Track and Breakthrough Therapy designations from the FDA and Priority Medicines designation from the European Medicines Agency, tividenofusp alfa represents a significant advancement in addressing the unmet need for therapies targeting central nervous system manifestations of Hunter syndrome. Autolus Therapeutics plc (NASDAQ: AUTL) will present updated clinical data from its CARLYSLE study of obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-cell therapy with a fast off-rate binding domain, in patients with severe refractory systemic lupus erythematosus at the American College of Rheumatology Convergence 2025. Initial findings demonstrated a manageable safety profile with no dose limiting toxicities, immune effector cell-associated neurotoxicity syndrome, or Grade ≥2 cytokine release syndrome, along with SLEDAI-2K score reductions and clinical benefit observed in all patients, including three who achieved complete renal response. The presentation on October 28, 2025, will feature updated follow-up data from this ongoing Phase I study, marking an important milestone in Autolus's expansion beyond oncology into autoimmune diseases with its proprietary CAR T platform that has already delivered AUCATZYL® as its first marketed therapy. Editas Medicine, Inc. (NASDAQ: EDIT) reported in vivo proof-of-concept data for EDIT-401, achieving ≥90% mean LDL-cholesterol reduction within 48 hours in non-human primates and similar results in mouse models with high baseline LDL-C. The experimental one-time therapy uses CRISPR/Cas9 nuclease with dual gRNAs delivered via LNP to disrupt negative regulatory elements, resulting in a ≥6-fold mean increase in LDLR protein in the liver. "The in vivo proof-of-concept data presented today reinforce the potential impact of our differentiated upregulation strategy," said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer of Editas Medicine. "In preclinical non-human primate studies, EDIT-401 achieved robust efficacy data with a ≥90% mean LDL-C reduction. These data strengthen our conviction that EDIT-401 represents a novel therapeutic approach with the potential to significantly improve outcomes for people living with high LDL cholesterol." The durable effects were maintained in mouse models throughout a three-month study period, supporting Editas's approach of functionally upregulating LDLR rather than traditional knockdown strategies. As the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines, Editas continues advancing its pipeline of precision in vivo gene editing medicines. Xencor, Inc. (NASDAQ: XNCR) recently announced the upcoming presentation of initial Phase 1 results for XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with clear cell renal cell carcinoma at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. The tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody targets ENPP3, an antigen highly expressed on kidney cancers with minimal expression on normal tissues, leveraging Xencor's proprietary platform that enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density. The presentation will include detailed safety analysis and efficacy results from the target dose range of the ongoing dose-escalation study (NCT05433142), with management hosting a webcast to discuss findings from this novel therapeutic approach that activates T cells for highly potent and targeted lysis of tumor cells while potentially sparing normal cells. Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES CITED 1. https://www.openpr.com/news/4225415/longevity-and-wellness-biotech-market-hits-new-high-major 2. https://www.pharmiweb.com/press-release/2025-10-14/cell-therapy-market-2035-driving-breakthroughs-in-oncology-and-regenerative-medicine 3. https://www.openpr.com/news/4225415/longevity-and-wellness-biotech-market-hits-new-high-major